Contrive Datum Insights has published "Next Generation Sequencing Market Size, Share & Industry Analysis, By Product (Consumables, Platforms, Data Analysis, Sample preparation, Target Enrichment, Others), Technology (WGS, Whole Exome Sequencing, DNA-based, RNA-based), Application (Oncology, Diagnostics and Screening, Oncology Screening, Sporadic Cancer, Inherited Cancer, Companion Diagnostics, Other Diagnostics, Clinical Investigation, Infectious Diseases, Inherited Diseases, Idiopathic Diseases, Non-communicable/Other Diseases, NIPT, Aneuploidy, Microdeletions, PGT, Newborn Genetic Screening, Single Gene Analysis, HLA Typing/Immune System Monitoring, Metagenomics, Epidemiology & Drug Development, Agrigenomics & Forensics, Consumer Genomics), Workflow (NGS Library Preparation Kits, Semi-automated Library Preparation, Automated Library Preparation, Clonal Amplification, NGS Data Analysis, NGS Primary Data Analysis, NGS Secondary Data Analysis, NGS Tertiary Data Analysis), End user (Academic & Research Institutes, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Others), and Regional Forecast, 2026-2034". The study sizes the global next generation sequencing market at USD 14.51 billion in 2025 and projects growth from USD 16.61 billion in 2026 to USD 49.09 billion by 2034, a compound annual growth rate of 14.5% across the forecast period.
Next generation sequencing covers the instruments, reagent kits, consumables and data analysis software and services used to determine the order of nucleotides in DNA and RNA at high throughput, replacing the slower single-target sequencing methods used previously. It spans whole genome and whole exome sequencing platforms, the library preparation and target enrichment kits that prepare samples for a sequencing run, and the primary, secondary and tertiary bioinformatics software that turns raw sequencing reads into a usable result. Buyers include academic and hospital genomics laboratories, pharmaceutical and biotechnology companies running drug discovery and companion diagnostics programs, and public health and reproductive health screening programs.
Declining per-sample sequencing cost accelerating clinical adoption
Declining per-sample sequencing cost accelerating clinical adoption is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 14.5% a year, the product lines exposed to it move fastest: Data Analysis compounds at 20.26%, taking its share of revenue from 13.99% to 22% and its value from USD 2.03 billion to USD 10.8 billion.
On the upside, the study's bull case assumes sequencing reagent costs fall faster than the base case and companion diagnostics reimbursement expands into more markets sooner, pulling forward clinical adoption, which would take 2034 revenue to USD 56.45 billion rather than the USD 49.09 billion base case.
However, reagent and consumables pricing stays firmer than expected and reimbursement expansion for companion diagnostics and NIPT slows in major markets, delaying the shift from research to routine clinical use, which would hold 2034 revenue to USD 42.71 billion. Consumables, which carries 37.97% of 2025 revenue, already grows at only 13.06% against the market's 14.5%, so the largest part of the base is also its slowest.
Key Players Compete on Consumables Volume and Data Analysis Growth
Competition in the global next generation sequencing market runs along the product axis rather than the regional one. Consumables holds 37.97% of 2025 revenue at USD 5.51 billion and remains the largest line through 2034 at 34%, making it the position hardest for a challenger to take. Data Analysis, growing at 20.26%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 14.51 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Product | Consumables | 37.97% · USD 5.51 billion | — |
| Technology | WGS | 29.98% · USD 4.35 billion | — |
| Application | Oncology | 16.61% · USD 2.41 billion | Newborn Genetic Screening 19.77% |
| Workflow | NGS Library Preparation Kits | 19.99% · USD 2.9 billion | Automated Library Preparation 18.86% |
| End user | Academic & Research Institutes | 35.01% · USD 5.08 billion | Hospitals & Clinics 16.15% |
- Based on regional analysis, North America led the global next generation sequencing market in 2025 with 41.97% of global revenue at USD 6.09 billion, reaching USD 18.66 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 21.99% in 2025 to 26.99% in 2034, with revenue growing from USD 3.19 billion to USD 13.25 billion.
- Middle East and Africa remains the smallest region throughout, at 5.03% of 2025 revenue and 4.99% by 2034.
- Data Analysis is projected to grow at 20.26% over the forecast period, the fastest of any product line.
- The United States is the largest single country market at USD 5.18 billion in 2025, 35.7% of global revenue.
The report segments the market across five axes; by product, and by technology, application, workflow and end user; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 42.71 billion and USD 56.45 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.